Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyCareFirst Neuropsychological Testing Policy Update…
    Ask Trek AI about this page
    RetiredCareFirstPolicy N/A

    Neuropsychological Testing

    Customize your policy alerts

    Sign up for all CareFirst policy alerts

    Know when CareFirst releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and investigational uses of neuropsychological testing for CareFirst members, adopting MCG Care Guidelines for clinical criteria and applicability; affects providers requesting or performing neuropsychological assessments for diagnosis, pre/postoperative evaluation, or rehabilitation planning.

    Policy Summary
    PayerCareFirst
    PolicyNeuropsychological Testing (RETIRED)
    Policy CodePolicy N/A
    Change TypeAdopted external MCG criterialocal policy retired
    Effective DateMar 1, 2026
    Last ReviewOct 8, 2025
    Next Review DateOct 8, 2025
    Key ActionVerify member contract and benefits and reference MCG Care Guidelines at carefirst.access.mcg.com before requesting or performing neuropsychological testing.
    SourceLink
    POLICY UPDATE CHANGES

    CareFirst has adopted the position of MCG Care Guidelines® Neuropsychological Testing along with its proprietary clinical criteria for medical necessity and clinical appropriateness.

    Local detailed criteria in this document are retired in favor of MCG criteria.

    Neuropsychological testing is considered medically necessary as outlined in the Policy Guidelines; testing for other conditions is investigational per TEC criteria.

    up to 8htypical maximum testing time before extra documentation requested
    Adopted MCG

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    source for medical necessity criteria
    Retiredlocal policy status
    Examples listedexample test batteries

    Coverage Criteria

    Medically Necessary Indications

    Covered when ALL of the following are met (see MCG Care Guidelines for full criteria):

    Adoption of external criteria: CareFirst has adopted MCG Care Guidelines® Neuropsychological Testing; medical necessity determined per MCG proprietary criteria.

    Providers must reference MCG criteria at carefirst.access.mcg.com.

    Medically necessary indications (examples): Neuropsychological testing is considered medically necessary for patients with known brain damage or risk for brain damage, including cerebrovascular disorders; most traumatic brain injuries (including concussion, diffuse axonal injury, contusions, hematomas, skull fractures, or seizures associated with traumatic injury); hydrocephalus; Alzheimer disease; Parkinson disease; multiple sclerosis; Huntington's chorea; tumor; infections; and for epilepsy pre-surgical planning and post-operative evaluation.

    This list is illustrative; authoritative indications are in the adopted MCG criteria.

    Experimental / Investigational

    Considered experimental/investigational when ALL of the following apply (per BCBSA/TEC criteria assessment):

    Investigational uses: Neuropsychological testing for conditions that do not involve known brain damage or a risk for brain damage is considered experimental/investigational because it fails to meet BCBSA/TEC assessment criteria (including insufficient evidence that the testing permits conclusions about effects on health outcomes, improves net health outcome, is as beneficial as alternatives, and demonstrates improvement outside investigational settings).

    Assessments do not require regulatory approval; lack of evidence in non-brain-damage settings supports investigational stance.

    Benefits are not provided for diagnostic or treatment services related to learning, curriculum planning, educational achievement, or special education programs provided under the Individuals with Disabilities Education Act (IDEA) — including IEP or IFSP — or Section 504 (504 Plan). These educational assessments and related services are the responsibility of the educational system and are excluded from coverage under this policy.

    Providers must verify member contract provisions and benefit limitations prior to service; specific contract exclusions, restrictions, or prior authorization requirements take precedence over this clinical policy.

    Neuropsychological testing for conditions that do not involve known brain damage or a risk for brain damage is considered experimental/investigational and not covered because current evidence does not demonstrate improved net health outcomes or benefit over alternatives for these indications. The policy applies TEC/BCBSA criteria which require demonstrated benefit, generalizability outside investigational settings, and favorable comparison to established alternatives.

    Examples and rationale in the literature review indicate that testing in non–brain-damage situations has not been shown to produce meaningful improvement in outcomes, and therefore such uses fail to meet the evidentiary thresholds required for coverage.

    Coding and Time Thresholds

    Codes not specified in policymixed
    not specifiedNo explicit CPT/HCPCS/ICD-10 codes listed in this policy document; examples of test batteries are named but billing codes are not provided.
    Testing time threshold
    Maximum typical total testing timeUp to 8 hours for the complete battery including administration, scoring and interpretation
    Action when threshold exceededIf testing time exceeds 8 hours, submit documentation indicating medical necessity for extended testing time
    Factors affecting evaluation lengthDepends on diagnosis, level of impairment, motivation, endurance, and ability to cooperate

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization and Benefit Verification

    Some services, devices, drugs, and places of service require prior authorization. Always check the member's contract for benefits; specific contract provisions, restrictions, and exclusions take precedence over these clinical criteria. Verify member contract and benefits and obtain prior authorization when required by the member's plan.

    • Prior authorization may be required for certain services, places of service, devices, or drugs
    • Member contract and benefits override policy clinical criteria
    • Verify eligibility and benefits before scheduling services
    Step Therapy

    No Step Therapy Protocols Specified

    No step therapy protocols for neuropsychological testing are specified in this policy. Follow any contract-specific prior authorization or utilization management requirements if they exist on the member's plan.

    • If the member's contract includes step therapy or other utilization controls, those contract-specific rules apply

    Background

    Neuropsychological testing is a battery-based assessment of cognitive functions — including memory, intellectual ability, perceptual-motor skills, language, and behavior — administered with standardized instruments and interpreted by qualified clinicians. Testing is typically used to identify cognitive deficits, assist differential diagnosis between neurogenic and psychogenic syndromes, inform prognosis, and guide rehabilitation or surgical planning (for example, pre- and post–epilepsy surgery evaluation).

    Typical test batteries include instruments such as the Halstead-Reitan, WAIS-IV, WMS-IV, Luria-Nebraska, and Wisconsin Card Sorting Test. Results are documented in a written report. CareFirst has adopted the MCG Care Guidelines® for specific medical necessity criteria, and this local policy has been retired in favor of the MCG guidance.

    Definitions

    Neuropsychological testing — definition
    DefinitionA battery-based assessment of cognitive skills performed with standardized tests to identify deficits in communication, intellectual ability, perceptual-motor function, feelings and behavior, documented in a written report
    PurposeUsed to diagnose neuropsychological deficits, determine prognosis, and assist with long-term rehabilitation planning
    Typical test batteries (examples)Halstead-Reitan, WMS-IV, WAIS-IV, Luria-Nebraska, Wisconsin Card Sorting Test
    Experimental/Investigational — definition and application
    DefinitionServices or supplies deemed experimental/investigational are those in developmental stages or lacking sufficient evidence per BCBSA MPS/TEC assessment criteria (all five criteria must be met)
    BCBSA MPS/TEC criteria (summary)
    Policy Summary
    PayerCareFirst
    PolicyNeuropsychological Testing (RETIRED)
    Policy CodePolicy N/A
    Change TypeAdopted external MCG criterialocal policy retired
    Effective DateMar 1, 2026
    Last ReviewOct 8, 2025
    Next Review DateOct 8, 2025
    Key ActionVerify member contract and benefits and reference MCG Care Guidelines at carefirst.access.mcg.com before requesting or performing neuropsychological testing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Time ThresholdsProvider Actions and AuthorizationBackgroundDefinitions
  1. When in doubt, confirm requirements during benefit verification/prior authorization
  2. Documentation Required

    Documentation Requirement for Extended Testing Time

    Typically, the test battery will require up to 8 hours to perform, including administration, scoring and interpretation. If total testing time exceeds 8 hours, submit documentation indicating the medical necessity for the extended testing time; such documentation may be requested during review.

    • Typical total testing time: up to 8 hours (administration, scoring, interpretation)
    • If testing exceeds 8 hours, provide supporting documentation of medical necessity
    Denial Risk

    Requests Not Meeting Policy Guidelines

    Requests that do not meet the Policy Guidelines or the contract-specific coverage criteria may be considered investigational or denied. Ensure submitted requests include documentation that demonstrates medical necessity per the Policy Guidelines and applicable contract terms.

    • Services not meeting Policy Guidelines may be deemed experimental/investigational and are subject to denial risk
    • Include sufficient clinical documentation to support medical necessity per policy and member contract
    1) Final regulatory approval; 2) Evidence permitting conclusions on health outcomes; 3) Improves net health outcome; 4) As beneficial as established alternatives; 5) Improvement attainable outside investigational settings
    Application to neuropsychological testingTesting for situations that do not involve brain damage or risk of brain damage is considered experimental/investigational because it has not been shown to improve outcomes outside investigational settings